More funds for AMR R&D

Share the article
Share on email
Share on twitter
Share on linkedin
Crédit : Pixabay

Published in the Linksbridge Weekly News Round-Up
 
Mentions: CARB-X, Accelerate, diagnostics, sepsis, AMR, Selux, BARDA, Crestone, drugs, C. diff
 
June 9, 2021 — Boston University-led nonprofit CARB-X announced Tuesday that it will give Arizona-based Accelerate Diagnostics $578,000 (plus up to $2.1 million in milestones) to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections.
 
In other antimicrobial resistance news, Boston’s Selux Diagnostics announced Tuesday an additional $14.6 million award from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid antimicrobial susceptibility testing (AST) platform. This latest tranche of funding – part of the company’s milestone-based contract with BARDA – was released after Selux completed a clinical trial that confirmed the platform’s ability to accurately provide AST results for a “broad antibiotic menu,” the company’s press release said.
 
Also on Tuesday, Colorado-based small molecule drug developer Crestone announced that it has enrolled the first patient in a Phase 2 trial of its novel antibiotic candidate (CRS3123) for treatment of C. difficile infections.
 
MORE INFORMATION:
 
CARB-X press release
Selux press release
Crestone press release